Total of 57 companies: 1.67 trillion won….2158 billion won compared to 2019, an increase of 14.8%
R&D ratio, which is the largest of sales, 9.65%, 0.82%p
Hanmi Pharm maintains the lead of KRW 226.1 billion., Yuhan Corporation, shoulder to shoulder with KRW 222.6 billion
Last year, due to Corona 19, pharmaceutical companies were also struggling with poor performance, but R&D expenses were found to have increased significantly.
As a result of the total R&D expenditures of 57 listed pharmaceutical companies that have published their 2020 business report by the 21st, the total R&D expenditure is estimated to be 1.6728 billion won, an increase of 2158 billion won and 14.8% from 2019.
In contrast to the sales growth of less than 5% during the same period, the increase in R&D expenditure was double digits, three times the increase in sales.
Accordingly, the ratio of R&D to 57 companies’ sales also averaged 9.65%, up 0.82%p from 2019, close to 10%.
In terms of the number of companies, the R&D expenditure of 44 companies, the vast majority of the 57 listed pharmaceutical companies surveyed, increased from 2019, and the R&D ratio to sales increased by 36 out of 57 companies.
As the R&D expenditure of one of the four listed pharmaceutical companies increased, the total R&D expenditure and the R&D ratio to sales increased significantly, but Yuhan Corporation’s influence was largely affected.
Yuhan Corporation’s R&D expenditures rose from 1382 billion won in 2019 to 2226 billion won last year, 83.8 billion won, a 61.0% increase, and Hanmi Pharmaceutical’s 200 billion won.
Yuhan contributed more than one-third of the combined R&D expenditure increase of 2158 billion won in 57 listed pharmaceutical companies last year.
Following Yuhan Corporation, it was confirmed that the R&D expenditure of six companies increased by more than 10 billion won, including Ildong Pharmaceutical 21.2 billion won, Hanmi Pharmaceutical 16.4 billion won, Chong Kun Dang 11.6 billion won, Ilyang Pharmaceutical 11.2 billion won, and JW Joongwae Pharmaceutical 10 billion won.
On the other hand, 13 companies including Hanall Biopharma, Boryeong Pharmaceutical, and Hyundai Pharm decreased their R&D expenditures from 2019, but none of them decreased by more than 5 billion won.
In terms of annual R&D expenditure, Hanmi Pharm was the largest at 2261 billion won, followed by Yuhan Corporation at 222.6 billion won.
Next, Green Cross maintained 100 billion won at 159.9 billion won, Chong Kun Dang at 149.7 billion won, and Daewoong Pharmaceutical at 144.5 billion won.
Following this, Dong-A ST invested more than 50 billion won in R&D with 79.4 billion won, Ildong Pharmaceutical 77.8 billion won, and JW Joongwae Pharmaceutical 55.7 billion won.
In addition, Boryeong Pharm, Ilyang Pharm, Daewon Pharm, and Samjin Pharm followed by 30 billion units, while Huons, Korea United Pharm, Samcheondang Pharm, Jeil Pharm, and Bukwang Pharm were counted at 20 billion units.
In addition, the R&D expenditure scale of Handok, Dongwha Pharm, Dongkuk Pharm, Ankuk Pharm, Youngjin Pharm, Hwanin Pharm, Daehwa Pharm, Kwangwon Pharm, Donggu Bio Pharm, Hanall Biopharma, Estipharm, Hana Pharm, Kwangdong Pharm, Kyungdong Pharm, etc. Exceeded a billion.
The ratio of R&D to sales was 21.00% for Hanmi Pharm, the only surpassing 20%, 16.50% for BC World Pharmaceutical, 15.95% for Hanall Biopharma, and 15.30% for Daewoong Pharmaceutical, exceeding 15%.
In addition, Samcheondang Pharmaceutical was followed by 14.55%, Ildong Pharmaceutical at 14.00%, Daehwa Pharmaceutical at 13.90%, Yuhan Corporation at 13.70%, Bukwang Pharmaceutical at 13.62%, Samjin at 13.23%, and Donga ST at 13.00%.
In addition, Ankuk Pharmaceutical 11.85%, Korea United Pharmaceutical 11.49%, CMG Pharmaceutical 11.49%, CMG Pharmaceutical 10.70%, Estipharm 10.64%, Green Cross 10.60%, Daewon Pharmaceutical 10.52%, Donggu Bio Pharmaceutical 10.20%, It was confirmed that Ilyang Pharmaceutical invested more than 10% of sales at 10.00% in R&D.
Copyright © Unauthorized reproduction and redistribution of medical news is prohibited.